Miglustat

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 430 publications

INVESTIGATION OF DIPYRIDAMOLE-ELICITED SIGNALING IN THE BRAIN OF NIEMANN PICK TYPE C MICE: A MULTI-OMIC STUDY.

INVESTIGATION OF DIPYRIDAMOLE-ELICITED SIGNALING IN THE BRAIN OF NIEMANN PICK TYPE C MICE: A MULTI-OMIC STUDY.

Journal: Brain research bulletin

Published: October 30, 2025

Drug-induced urinary incontinence in pediatric patients: A disproportionality analysis of the FDA Adverse Event Reporting System.

Drug-induced urinary incontinence in pediatric patients: A disproportionality analysis of the FDA Adverse Event Reporting System.

Journal: Medicine

Published: October 28, 2025

NEO1 modulates the A1 astrocyte polarization in subarachnoid hemorrhage through the cPLA2-MAVS signaling pathway.

NEO1 modulates the A1 astrocyte polarization in subarachnoid hemorrhage through the cPLA2-MAVS signaling pathway.

Journal: Journal of neuroinflammation

Published: October 20, 2025

Correction: Miglustat ameliorates isoproterenol-induced cardiac fibrosis via targeting UGCG.

Correction: Miglustat ameliorates isoproterenol-induced cardiac fibrosis via targeting UGCG.

Journal: Molecular medicine (Cambridge, Mass.)

Published: September 23, 2025

Visual Recovery and Neurological Stabilization Following Miglustat Treatment in Pediatric CLN3 Disease.

Visual Recovery and Neurological Stabilization Following Miglustat Treatment in Pediatric CLN3 Disease.

Journal: Journal of child neurology

Published: September 18, 2025

Is Miglustat an Effective Treatment for CLN3 (Batten) Disease?

Is Miglustat an Effective Treatment for CLN3 (Batten) Disease?

Journal: Neurology

Published: September 09, 2025

Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.

Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.

Journal: Neurology

Published: September 09, 2025

Miglustat does not impact clinical progression in patients with spastic paraplegia type 11.

Miglustat does not impact clinical progression in patients with spastic paraplegia type 11.

Journal: Neurogenetics

Published: August 28, 2025

Miglustat as a Treatment for Adults with Tangier Disease Neuropathy: The MUSTANG N-of-1 Trial with 21 months Clinical Observation.

Miglustat as a Treatment for Adults with Tangier Disease Neuropathy: The MUSTANG N-of-1 Trial with 21 months Clinical Observation.

Journal: Neurology and therapy

Published: August 21, 2025

The SGLT2 Inhibitor Dapagliflozin Disrupts the Cell Cycle at High Concentrations Without Altering Glycosphingolipid (De Novo)Biosynthesis.

The SGLT2 Inhibitor Dapagliflozin Disrupts the Cell Cycle at High Concentrations Without Altering Glycosphingolipid (De Novo)Biosynthesis.

Journal: International journal of molecular sciences

Published: August 20, 2025

New advances in treating late-onset Pompe Disease: A narrative review.

New advances in treating late-onset Pompe Disease: A narrative review.

Journal: European journal of pediatrics

Published: July 28, 2025

Ketogenic Diet in Niemann-Pick Type C: Insights From a Case Report.

Ketogenic Diet in Niemann-Pick Type C: Insights From a Case Report.

Journal: International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience

Published: July 09, 2025

Showing 1-12 of 430

Last Updated: 02/24/2026